OncoNano Raises $50 Million from China Investor for pH-based Cancer Products
June 17, 2021 at 08:32 AM EDT
OncoNano Medicine, located in a suburb of Dallas , Texas , raised $50 million for its novel pH-based cancer products in a B round led by Advantech Capital, a China cross border investor. Proceeds of the round will be used to support the Phase II US/EU clinical trials for pegsitacianine, a real-time imaging agent used in intraoperative surgical resection of solid tumors, and to accelerate development of ONM-501, a novel immunoncology molecule. OncoNano was founded by Jinming Gao, PhD, who received his BS from Peking University and PhD from Harvard. More details.... Share this with colleagues: // //
